ICH E6(R3) was adopted in 2023 as the first full revision of the GCP guideline in over two decades. The core document introduced risk-based quality management as a foundational principle. It also restructured sponsor oversight obligations and modernised the framework for data integrity and quality tolerance limits. Importantly, that core text applies to all interventional clinical trials.

ICH E6(R3) Annex 2: What the New GCP Rules for Decentralised and Platform Trials for APAC Sponsors

ICH E6(R3) Annex 2 goes further. It covers decentralised trial elements and platform trial designs, setting the GCP framework for remote visits, home health nursing, and direct-to-participant drug delivery. Master protocol designs for multi-arm or adaptive studies also fall within its scope. For APAC sponsors, Annex 2 is the part of the revised GCP standard that most directly affects protocol design. It governs how oversight obligations apply when participants interact with the study outside a clinical site.

Key takeaways

  • ICH E6(R3) Annex 2 applies to trials that include decentralised elements or platform trial designs. It does not mandate either. Instead, it sets the GCP framework within which sponsors may use them, subject to local regulation and ethics approval.
  • APAC markets are implementing Annex 2 at different speeds. Australia, Singapore, and South Korea have moved fastest. India is implementing the core E6(R3) standard but retains domestic constraints on specific decentralised elements such as direct-to-participant drug delivery.
  • Remote informed consent, home health nursing visits, and ePRO are the most commonly used decentralised elements in APAC clinical trials. Each requires sponsor documentation of the risk assessment, quality approach, and local regulatory compliance check.
  • Platform trials under Annex 2 require a master protocol, a shared governance structure, and sub-study-specific ethics and regulatory review. In APAC, this adds complexity in markets where regulatory notifications are required separately for each sub-study.
  • Sponsors writing protocols for APAC trials in 2026 should confirm with their CRO and local ethics committee which Annex 2 provisions apply. They should also check whether local regulatory guidance supplements or limits the ICH standard.

What ICH E6(R3) Annex 2 covers

The main body of ICH E6(R3) sets out core GCP principles: sponsor responsibilities, investigator duties, IRB/IEC requirements, and essential documents. Annex 1 supplements this for traditional interventional clinical trials with investigational medicinal products. ICH E6(R3) Annex 2, by contrast, covers two types the original E6(R1/R2) framework did not adequately address: decentralised trial elements and platform trial designs.

Decentralised clinical trial elements under Annex 2

A decentralised clinical trial uses one or more elements that allow participant interactions to occur outside a traditional clinical site. These include remote video visits, home health nursing visits for sample collection or vital sign measurement, and direct-to-participant drug delivery. Electronic clinical outcome assessments on participant devices also fall within this category.

ICH E6(R3) Annex 2 requires sponsors who use these elements to conduct a documented risk assessment for each one. The assessment must identify the GCP risks of the decentralised element and define the quality measures the sponsor will apply to control them. It must also confirm that data collected outside the site will meet the same integrity standards as on-site data. This risk assessment is not a formality. Regulators reviewing applications with decentralised elements are increasingly requesting this in the protocol or in a study-specific quality plan.

Annex 2 also specifies that the sponsor must qualify any third-party provider supporting decentralised elements, such as a home health nursing agency or a telehealth platform vendor. Under ICH E6(R3) Annex 2, these vendors sit within the sponsor’s quality oversight framework, not outside it. The protocol or a separately documented agreement must address how the sponsor monitors their performance and manages deviations.

Platform trials and master protocols under Annex 2

A platform trial uses a single master protocol to evaluate multiple treatments. Arms may be added or removed as the trial progresses, based on pre-specified decision rules. Basket trials, umbrella trials, and adaptive platform trials all fall under this design category. They are common in oncology, where APAC markets have active multi-arm programmes in both academic and sponsored settings.

ICH E6(R3) Annex 2 sets out the governance requirements for platform trials. The master protocol must define the overall trial objectives and the shared statistical framework. It must also specify the governance body responsible for platform-level decisions and the provisions that apply to each sub-study. Ethics approval and regulatory notification must cover both the master protocol and each active sub-study. The Annex also clarifies the chain of responsibility when a sponsor adds a new arm. The master protocol governance body must authorise the addition. The relevant ethics committee must review the sub-study protocol. The regulatory authority must also be notified per national requirements.

How APAC markets are implementing ICH E6(R3) Annex 2

Implementation of ICH E6(R3) Annex 2 across APAC is uneven. Markets that have participated most actively in the ICH process and adopted guidelines without substantial domestic modification are furthest along. However, markets with stronger domestic frameworks have added their own requirements, creating additional compliance steps for sponsors.

Australia and Singapore: fullest adoption of Annex 2 provisions

Australia’s TGA adopted ICH E6(R3) and issued supplementary guidance on decentralised trial elements that aligns with Annex 2. The TGA accepts risk-based quality plans for decentralised elements. It permits remote informed consent, home health visits, and ePRO in Australian-site trials. The sponsor must document the quality assurance approach, and the ethics committee must approve the design. For platform trials, the TGA’s approach to master protocol submissions is consistent with the Annex 2 governance requirements.

Singapore’s HSA similarly operates within the ICH E6(R3) Annex 2 framework. Singapore has been an early adopter of decentralised trial elements in APAC, with a pragmatic approach to remote visits and electronic outcome assessments. For APAC studies that include Singapore as a first-in site or an early-entry market, Annex 2 requirements can generally be met without additional regulatory negotiation. The standard protocol approval process covers them.

South Korea: domestic guidance supplements the Annex 2 standard

MFDS has issued domestic guidance on decentralised clinical trials that supplements ICH E6(R3) Annex 2 rather than replacing it. Specifically, South Korean guidance requires additional documentation for remote visit platforms and requires that home health providers hold MFDS-recognised certifications. Sponsors using ICH E6(R3) Annex 2 as their quality framework for a Korean-site study should therefore cross-check each decentralised element against the MFDS supplementary guidance before finalising the protocol. Platform trial designs, particularly for oncology, are well-accepted by MFDS. The sub-study notification process is also defined and predictable for sponsors with prior MFDS experience.

India: core E6(R3) with constraints on specific elements

India has implemented ICH E6(R3) core principles through amendments to Schedule Y and the New Drugs and Clinical Trials Rules. However, CDSCO‘s domestic framework constrains certain decentralised elements that Annex 2 permits. Direct-to-participant drug delivery remains tightly regulated in India. The investigational product must be dispensed through or under the oversight of the investigator. Home delivery directly to participants is not permitted under current CDSCO rules without specific approval. Consequently, sponsors designing global trials with DTP drug delivery must treat India as a modified implementation site for this element.

Remote informed consent in India is permitted under eConsent provisions in the 2019 NDCT Rules amendment. However, the requirements for witness presence and process documentation are stricter than the flexible approach ICH E6(R3) Annex 2 envisions. eConsent is feasible at experienced Indian sites, but it requires site-specific setup and IRB approval of the eConsent documentation. ePRO and eCOA are generally accepted. Home health nursing visits are feasible with qualified agencies. However, they require ethics committee review of the specific home visit protocol. Overall, India is not a restricted market for decentralised elements. Sponsor teams should, however, verify which Annex 2 provisions apply domestically before finalising the protocol.

What changes for sponsors running APAC trials in 2026

Three practical changes follow from ICH E6(R3) Annex 2 for sponsors designing APAC trials now.

First, any protocol that includes a decentralised element must contain a documented risk assessment for that element. This is not optional. Ethics committees in Australia, Singapore, and South Korea are requesting it. Some committees are now issuing queries when a protocol describes a remote visit or home health element without a corresponding quality assurance section. Adding this documentation after the protocol is submitted typically delays approval by four to eight weeks.

Second, third-party vendors supporting decentralised elements must be qualified by the sponsor under a documented oversight framework. This applies to home health nursing agencies, telehealth platform providers, and direct-to-participant logistics providers. Sponsors new to these vendor types should start qualification activities before finalising the protocol, not after site activation.

Third, platform trial protocols must include the master protocol governance provisions that Annex 2 requires. The governance section must be explicit about the governance body’s authority and the process for adding or removing arms. Ethics committees in APAC are increasingly familiar with Annex 2 governance requirements. They expect to see these reflected in submission documents.

What stays the same under Annex 2

ICH E6(R3) Annex 2 does not change the fundamental GCP obligations that apply to all clinical trials. Investigator qualifications, IRB/IEC requirements, data integrity standards, and adverse event reporting obligations all remain as defined in the core E6(R3) text and Annex 1. Annex 2 adds requirements specifically for decentralised elements and platform designs. It does not create a separate or lighter regulatory pathway for trials that use these designs.

Sponsors with established GCP compliance frameworks under E6(R2) are not starting from scratch. What ICH E6(R3) Annex 2 requires is explicit coverage of the additional risk areas that decentralised elements and platform designs introduce. For most experienced APAC sponsors, this is an extension of existing quality management practice, not a replacement.

Conclusion

ICH E6(R3) Annex 2 formalises the GCP framework for clinical trial designs that sponsors are already using in APAC. Decentralised elements and platform trials are not new in the region. What Annex 2 provides, however, is a structured, regulator-accepted quality framework for implementing them. APAC markets are adopting this framework at different speeds. Domestic regulatory constraints in India and some other markets mean global Annex 2 protocols need country-specific compliance checks. Sponsors who build these checks in before the first ethics submission avoid the queries and delays that arise when a constraint is discovered mid-review.


Running a Decentralised or Platform Trial in APAC?

If you are designing an APAC trial with decentralised elements or a platform design, Credevo can help build ICH E6(R3) Annex 2 compliance into the protocol before submission. We work across India, Australia, Singapore, South Korea, Thailand, and Malaysia. Please fill out the form below to connect with our team.

Provide your work email, where we can contact you.

Frequently asked questions

Does ICH E6(R3) Annex 2 apply to all clinical trials in APAC?

ICH E6(R3) Annex 2 applies to trials with decentralised elements such as remote visits, home health nursing, direct-to-participant drug delivery, or ePRO. It also applies to trials using platform or master protocol designs. It does not apply to standard site-based trials that do not include these features. The core ICH E6(R3) document applies to all interventional trials; Annex 1 applies to IMP-based interventional clinical trials specifically. APAC markets have adopted these standards at varying speeds and with varying degrees of domestic supplementation. The compliance picture for any specific trial depends on the markets included and the decentralised elements the sponsor plans to use.

Can sponsors use remote informed consent in India under ICH E6(R3) Annex 2?

Yes, with conditions. India permits electronic informed consent under the eConsent provisions introduced in the 2019 amendment to the NDCT Rules. The process must receive ethics committee approval. Documentation must meet CDSCO’s requirements, including electronic signature provisions and, in some cases, witness involvement. ICH E6(R3) Annex 2 envisions a risk-based approach to remote consent. This gives sponsors more flexibility than current CDSCO requirements allow. In practice, therefore, sponsors using eConsent in Indian-site trials must follow domestic regulatory requirements. Relying solely on the Annex 2 framework is not sufficient. Credevo’s regulatory team manages site-specific eConsent documentation and ethics submissions as part of study start-up for Indian-site trials.

What does ICH E6(R3) Annex 2 require for direct-to-participant drug delivery in APAC?

Annex 2 requires that sponsors using direct-to-participant drug delivery conduct a documented risk assessment. This covers product integrity during transport, chain of custody, participant receipt confirmation, and management of returns and unused product. The risk assessment must be reflected in the protocol or study quality plan. In practice, the permissibility of DTP drug delivery in any APAC market depends on domestic regulations, not only on the ICH GCP framework. India does not currently permit investigational product to be delivered directly to participants outside investigator oversight. Australia, Singapore, and South Korea permit DTP drug delivery with appropriate controls and ethics approval. Sponsors should map each target market’s domestic requirements for DTP before including this element in the global protocol design.

How do platform trials under ICH E6(R3) Annex 2 differ from standard multi-arm trials?

A standard multi-arm trial compares a fixed set of treatment arms against a control. All arms are specified in the protocol before ethics approval. A platform trial under Annex 2, by contrast, uses a master protocol governing a shared infrastructure. Arms are added or dropped as the trial progresses, based on pre-specified decision rules. The governance requirements differ significantly. Platform trials require a master protocol governance body with clearly defined authority over platform-level decisions. The statistical analysis framework must account for sharing a control arm across multiple experimental treatments. Sub-study-specific ethics and regulatory review is also distinct from the master protocol review. In APAC, the sub-study review process adds time in markets where each arm addition requires a separate regulatory notification. Sponsors should therefore plan the governance structure and regulatory notification sequence before initiating the master protocol ethics submission.

Which APAC markets have formally adopted ICH E6(R3) Annex 2?

Australia, Singapore, South Korea, and Japan have implemented ICH E6(R3) as their operative GCP standard. Each has also issued supplementary domestic guidance on specific elements. TGA, HSA, MFDS, and PMDA each operate within the ICH E6(R3) framework, including the Annex 2 provisions. India has implemented core E6(R3) principles through domestic amendments. However, it has not issued guidance that specifically references Annex 2 or resolves all domestic constraints on decentralised elements. Thailand, Malaysia, and Vietnam are implementing E6(R3), but their domestic guidance does not yet fully reflect Annex 2. As a result, sponsors running multi-country APAC trials should treat Annex 2 as the governing quality framework. They should also confirm domestic regulatory compatibility for each market-specific element before finalising the protocol.